Business Context and Reporting Period
Company: Theravance Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 5, 2025
Subject: Settlement of patent litigation regarding YUPELRI (revefenacin) inhalation solution.
Key Financial Metrics
This filing is a Current Report (Form 8-K) detailing a legal settlement and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Events
- Settlement Agreement: Theravance and Mylan entered into a settlement with Eugia Pharma Specialities Ltd. and affiliates regarding patent infringement claims under the Hatch-Waxman Act.
- Litigation Resolution: The agreement resolves ongoing litigation concerning Eugia's Abbreviated New Drug Application (ANDA) for a generic version of YUPELRI.
- Patents Involved: The settlement covers 13 specific United States Patents owned by Theravance and sub-licensed to Mylan.
- License Grant: Theravance and Mylan granted Eugia a royalty-free, non-exclusive license to manufacture and market the generic product in the U.S. on or after April 23, 2039.
- Regulatory Review: The settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.
- Remaining Litigation: Patent litigation remains pending against two other ANDA filers: Cipla Limited and Mankind Pharma Ltd.
Guidance, Outlook, and Risks
- Management Commentary: The filing confirms the resolution of one specific patent dispute while noting that others remain active.
- Risks and Contingencies: The settlement is contingent upon approval by federal regulatory bodies (DOJ and FTC). The company continues to face potential market entry risks from the remaining pending litigations against Cipla and Mankind Pharma.
- Unusual Items: The grant of a royalty-free license extending to 2039 is a significant long-term commercial arrangement resulting from the settlement.
Investor Verification Checklist
- Verify the status of the Department of Justice and FTC review of the settlement.
- Monitor the progress of pending litigation against Cipla Limited and Mankind Pharma Ltd.
- Assess the potential impact of the 2039 generic launch date on long-term YUPELRI revenue projections.
- Confirm the specific terms of the "certain exceptions" mentioned in the license grant.